VTVT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
vTv Therapeutics Inc (VTVT) is not a strong buy for a beginner, long-term investor at this moment. While the technical indicators show some bullish signals, the lack of significant recent news, poor financial performance, and absence of strong trading signals suggest a cautious approach. The stock has potential due to its promising pipeline, but the financials and lack of immediate catalysts make it less compelling for immediate investment.
The technical indicators show a bullish trend with MACD positively expanding, RSI in the neutral zone at 59.214, and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). The stock is trading near resistance levels (R1: 38.864), which could limit further upward movement in the short term.
The company's lead drug candidate, cadisegliatin, has received Breakthrough Therapy Designation and is progressing through Phase 3 trials. Analysts are optimistic about its potential approval and adoption, with high price targets ranging from $44 to $67.
The company reported zero revenue in Q4 2025, with a significant YoY revenue drop (-100%). Despite improvements in net income and EPS, the financials remain weak. Additionally, there are no significant hedge fund or insider trading trends, and no recent news to drive immediate momentum.
In Q4 2025, revenue dropped to 0 (-100% YoY), net income improved to -7,138,000 (+96.42% YoY), and EPS increased slightly to -0.57 (+3.64% YoY). Gross margin also dropped to 0 (-100% YoY), indicating weak financial health.
Analysts are bullish on the stock, with multiple Buy ratings and price targets ranging from $44 to $67. The optimism is driven by the potential of cadisegliatin to address unmet needs in type 1 diabetes, with projected peak sales of $2.15B by 2037.
